Correlation Between Arbutus Biopharma and ABVC Biopharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Arbutus Biopharma and ABVC Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Arbutus Biopharma and ABVC Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Arbutus Biopharma Corp and ABVC Biopharma, you can compare the effects of market volatilities on Arbutus Biopharma and ABVC Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Arbutus Biopharma with a short position of ABVC Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Arbutus Biopharma and ABVC Biopharma.

Diversification Opportunities for Arbutus Biopharma and ABVC Biopharma

-0.38
  Correlation Coefficient

Very good diversification

The 3 months correlation between Arbutus and ABVC is -0.38. Overlapping area represents the amount of risk that can be diversified away by holding Arbutus Biopharma Corp and ABVC Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on ABVC Biopharma and Arbutus Biopharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Arbutus Biopharma Corp are associated (or correlated) with ABVC Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of ABVC Biopharma has no effect on the direction of Arbutus Biopharma i.e., Arbutus Biopharma and ABVC Biopharma go up and down completely randomly.

Pair Corralation between Arbutus Biopharma and ABVC Biopharma

Given the investment horizon of 90 days Arbutus Biopharma Corp is expected to generate 0.65 times more return on investment than ABVC Biopharma. However, Arbutus Biopharma Corp is 1.54 times less risky than ABVC Biopharma. It trades about 0.12 of its potential returns per unit of risk. ABVC Biopharma is currently generating about -0.02 per unit of risk. If you would invest  250.00  in Arbutus Biopharma Corp on January 19, 2024 and sell it today you would earn a total of  23.00  from holding Arbutus Biopharma Corp or generate 9.2% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Arbutus Biopharma Corp  vs.  ABVC Biopharma

 Performance 
       Timeline  
Arbutus Biopharma Corp 

Risk-Adjusted Performance

7 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Arbutus Biopharma Corp are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively conflicting basic indicators, Arbutus Biopharma unveiled solid returns over the last few months and may actually be approaching a breakup point.
ABVC Biopharma 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days ABVC Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in May 2024. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Arbutus Biopharma and ABVC Biopharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Arbutus Biopharma and ABVC Biopharma

The main advantage of trading using opposite Arbutus Biopharma and ABVC Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Arbutus Biopharma position performs unexpectedly, ABVC Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ABVC Biopharma will offset losses from the drop in ABVC Biopharma's long position.
The idea behind Arbutus Biopharma Corp and ABVC Biopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.

Other Complementary Tools

Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Money Managers
Screen money managers from public funds and ETFs managed around the world
Transaction History
View history of all your transactions and understand their impact on performance
Commodity Directory
Find actively traded commodities issued by global exchanges
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm